Arbutus Biopharma (ABUS) Operating Leases (2019 - 2025)
Arbutus Biopharma (ABUS) posted Operating Leases of $199000.0 for Q4 2025, down 49.1% sequentially from $391000.0 in Q3 2025, and down 75.31% YoY from $806000.0 in Q4 2024.
Arbutus Biopharma (ABUS) Operating Leases (2019 - 2025) Analysis & Trends
Arbutus Biopharma has reported Operating Leases for 7 years, with the latest figure at $199000.0 in Q4 2025.
- Quarterly Operating Leases fell 75.31% year-over-year to $199000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $199000.0 (down 75.31% YoY) and the FY2025 annual result came in at $199000.0, down 75.31% from the prior year.
- Operating Leases declined to $199000.0 in Q4 2025 per ABUS's latest filing, from $391000.0 in the prior quarter.
- Over five years, Operating Leases peaked at $2.5 million in Q1 2021 and troughed at $199000.0 in Q4 2025.
- A 5-year average of $1.5 million and a median of $1.6 million in 2023 frame the typical range for Operating Leases.
- The sharpest annual moves came in 2021 and 2025: Operating Leases retreated 13.67% in 2021, then plunged 75.31% in 2025.
- Over 5 years, Operating Leases stood at $2.2 million in 2021, then declined by 18.65% to $1.8 million in 2022, then decreased by 26.01% to $1.3 million in 2023, then slumped by 39.99% to $806000.0 in 2024, then slumped by 75.31% to $199000.0 in 2025.
- According to Business Quant data, Operating Leases over the past three periods registered $199000.0, $391000.0, and $575000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Arbutus Biopharma | 922.95 Mn | 830.33 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 199,000.00 |
| Sep 30, 2025 | 391,000.00 |
| Jun 30, 2025 | 575,000.00 |
| Mar 31, 2025 | 626,000.00 |
| Dec 31, 2024 | 806,000.00 |
| Sep 30, 2024 | 978,000.00 |
| Jun 30, 2024 | 1.14 Mn |
| Mar 31, 2024 | 1.18 Mn |
| Dec 31, 2023 | 1.34 Mn |
| Sep 30, 2023 | 1.50 Mn |
| Jun 30, 2023 | 1.65 Mn |
| Mar 31, 2023 | 1.67 Mn |
| Dec 31, 2022 | 1.82 Mn |
| Sep 30, 2022 | 1.96 Mn |
| Jun 30, 2022 | 2.09 Mn |
| Mar 31, 2022 | 2.10 Mn |
| Dec 31, 2021 | 2.23 Mn |
| Sep 30, 2021 | 2.36 Mn |
| Jun 30, 2021 | 2.48 Mn |
| Mar 31, 2021 | 2.48 Mn |